MEDICUS PHARMA LTD. Operating Lease, Expense
MEDICUS PHARMA LTD. (MDCX) reported Operating Lease, Expense of $61.89 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2026-08-12
- MEDICUS PHARMA LTD. operating lease, expense for the quarter ending 2026-06-30 was $30.95K, a 0.00% increase year-over-year.
- MEDICUS PHARMA LTD. operating lease, expense for the quarter ending 2026-03-31 was $30.94K, a 0.00% decline year-over-year.
- MEDICUS PHARMA LTD. operating lease, expense for the quarter ending 2025-12-31 was $31.29K, a 0.00% change year-over-year.
- MEDICUS PHARMA LTD. operating lease, expense for the quarter ending 2025-09-30 was $30.59K, a 0.00% change year-over-year.
- MEDICUS PHARMA LTD. operating lease, expense for fiscal 2025 was $123.78K, a 0.00% change from fiscal 2024.
- MEDICUS PHARMA LTD. operating lease, expense for fiscal 2024 was $123.78K.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $30.95K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $61.89K 10-Q · filed 2026-08-12 | $93.18K derived: sum of 3 quarters · filed 2026-08-12 | $123.78K derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $30.94K 10-Q · filed 2026-05-14 | $62.24K derived: sum of 2 quarters · filed 2026-05-14 | $92.83K derived: sum of 3 quarters · filed 2026-05-14 | $123.78K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $31.29K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $61.89K derived: sum of 2 quarters · filed 2026-03-25 | $92.83K derived: sum of 3 quarters · filed 2026-08-12 | $123.78K 10-K · filed 2026-03-25 |
| 2025-09-30 | $30.59K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $61.54K derived: sum of 2 quarters · filed 2026-08-12 | $92.48K 10-Q · filed 2025-11-14 | $123.78K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $30.94K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $61.89K 10-Q · filed 2026-08-12 | $93.18K derived: sum of 3 quarters · filed 2026-08-12 | $123.78K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $30.95K 10-Q · filed 2026-05-14 | $62.24K derived: sum of 2 quarters · filed 2026-05-14 | $92.83K derived: sum of 3 quarters · filed 2026-05-14 | $123.78K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $31.29K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $61.89K derived: sum of 2 quarters · filed 2026-03-25 | $92.83K derived: sum of 3 quarters · filed 2026-03-25 | $123.78K 10-K · filed 2026-03-25 |
| 2024-09-30 | $30.59K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $61.54K derived: sum of 2 quarters · filed 2025-11-14 | $92.48K 10-Q · filed 2025-11-14 | |
| 2024-06-30 | $30.94K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $61.89K 10-Q · filed 2025-08-11 | ||
| 2024-03-31 | $30.95K 10-Q · filed 2025-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B |